Latest Articlesddd

Biocryst: A Major Game Changing Agreement

June 22, 2015 0

On Thursday June 18, 2015, we posted an article under “Today’s Highlights” at the Prohost website …

Prohost Letter #378 Part 2

June 9, 2015 0

Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The …

Immunogen: Defeating Advanced Ovarian Cancer and Other Malignancies

June 2, 2015 0

– Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. – The firm …

A Company Report

May 29, 2015 0

VASCULAR BIOGENICS OPERATING AS VBL THERAPEUTICS Vascular Biogenics Ltd., operating as VBL Therapeutics (VBLT) is a …

Xoma: Phase 3 Eyeguard-B Trial Is Good News for Gevokizumab

May 27, 2015 0

Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab …

Prohost Letter #378 Part 1

May 27, 2015 0

Prohost Letter #378 Part 1 Views and Visions TOP-TIER BIOTECHNOLOGY COMPANIES GILEAD We wrote a lot …

Immunotherapy at ASCO. What Do We Want to Hear?

May 22, 2015 0

For those who ask whether immunotherapy will have a dominant presence at ASCO, we confirm that …

Vertex: The FDA Advisory Committee Recommended Approval for Orkambi

May 13, 2015 0

AS WE AND PREDICTED, the FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC), voted in favor of approving …

The FDA Advisory Committee Voted in Favor of Amgen Melanoma Drug T-VEC and More Insight

April 29, 2015 0

The FDA Advisory Committee Voted 22-1 In Favor of Approval of Its Melanoma Immunotherapy T-VEC Yesterday’s …

Prohost Letter #377

April 21, 2015 0

Prohost Letter #377 PICKING BIOTECH FIRMS Before Investing in Them Raising the bar in designating small …

Celldex: Crossing the Border Towards a Higher Status

March 17, 2015 0

As you would observe when reading the most recent Prohost Letters, our recent enthusiasm for Celldex …

Prohost Letter #376

March 11, 2015 0

Prohost Letter #376 WHILE LOOKING AT THE BIOTECHS SCIENTIFIC FUNDAMENTALS We keep an eye on other …

Exelixis: On the Road Towards Accomplishments with Faster Steps

February 19, 2015 0

Exelixis Announces Acceptance of New Drug Application for Cobimetinib (NDA) in Combination with Vemurafenib for Treatment …

Aerie Pharmaceuticals Is Speeding Towards Improving the Magement of Glaucoma

February 11, 2015 0

AERIE PHARMACEUTICALS (AERI) A YOUNG BUT STRONG COMPETITOR IN THE GLAUCOMA HUGE MARKET – Aerie Pharmaceuticals …

Irrational Selloff Adding More Irrational Volatility

February 4, 2015 0

They jumped to call the biotech sector a bubble, accentuating its volatility. Instead of saying WOW …

Prohost Letter #375 Part 2

February 3, 2015 0

Prohost Letter #375 Part 2 Novel Breakthrough Cancer Immunotherapy Approaches PART 2 In Part 1 of this …

Prohost Letter #375 Part 1

January 29, 2015 0

Prohost Letter #375 Part 1 BIOTECHNOLOGY: THE BEGINNING OF A NEW ERA STATE- OF-THE-ART APPROACHES FOR THE …

Has the Time Come to Appreciate Agenus?

January 9, 2015 0

Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies Today’s news is good for …